OpenAI collaborated with longevity startup Retro Biosciences to create a micro AI model named GPT-4b micro, specialized in protein engineering. The model successfully redesigned proteins called Yamanaka factors, used to convert adult cells back into stem cells. The AI-generated proteins showed a remarkable 50-fold increase in efficiency compared to original versions, raising the potential for advancements in regenerative medicine by effectively rejuvenating old cells. While AI’s applications in life sciences could significantly expedite research timelines, the findings remain at proof-of-concept stage and moving towards clinical applications will be a challenge. OpenAI emphasizes transparency by planning to publish the research openly. This innovation could not only transform regenerative therapies but also raise biosecurity concerns regarding AI-designed proteins.

Source 🔗